Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential

21. October 2020 | 12:42 CET

BioNTech, Valeo Pharma, Pfizer - Starting signal!

  • Covid-19
Photo credits:

Who will make the race for the first approved Corona vaccine? Russia, China, and several North American suppliers are fighting for a place in the sun. The second and third parties should also benefit from the approval, as the demand is enormous among the nearly 8 billion inhabitants of the earth. One thing is clear; the winners of this almost macabre-sounding "Corona contest" will go through the roof. Those who receive late approval or no approval at all risk extinction. Admittedly, the world is looking at the long-awaited miracle cure. But there are easier ways for every individual to protect themselves against viruses.

time to read: 2 minutes by Stefan Feulner



Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author

On the home stretch!

Pfizer pushes forward. The U.S. pharmaceutical Company could apply for emergency approval of its Corona vaccine in the USA in November. According to Pfizer CEO Albert Bourla, the prerequisite is that efficacy and safety data are positive in the ongoing trials. An emergency approval would have the advantage that parts of the U.S. population, namely, the elderly or medical staff, could be vaccinated even before the official license.

The third week of November as the target

The North Americans, who are developing the active ingredient BNT162b2 in collaboration with the Mainz-based Company BioNTech, are aiming for the third week of November to apply for approval. Since the FDA requires data from at least half of the participants in the ongoing trials for a period of two months after the completion of vaccination, this would be the timeframe for an evaluation.

Most promising applicant

The vaccine from Pfizer and BioNTech is still considered one of the most promising in the fight against the virus. At the beginning of the month, the European Medicines Agency (EMA) confirmed that the testing of the active ingredient in the so-called rolling review process for approval in Europe. Similarly far as the German-American conglomerate, is the U.S. biotech Company, Moderna. The Company intends to apply for emergency approval in December. It remains exciting in the global battle for the "Corona contest."

Alternatives to vaccination

It remains to be seen how long it will take until a suitable vaccine is available on the market for all population groups and whether it is the final elimination of the pandemic. What each individual can do for himself, however, is to strengthen his immune system. For once, even the highly decorated virologists agree on this. It is also undisputed that viruses and pathogens can attack the body easier if the immune system is weak. One can bring about strengthening with healthy foods and drinks.

Nutritional supplements have a targeted effect

People who are healthy and eat a healthy and varied diet mostly supply their bodies with all the vitamins and minerals they need. Under certain circumstances, however, food supplements may be necessary. After operations, in the case of unbalanced nutrition, during pregnancy, or in the case of senior citizens, an undersupply of essential nutrients can occur.

At the pulse of time

Valeo Pharma is well in the running here. The Canadian Company markets a dietary supplement containing a highly effective antioxidant intended to support the immune system. The product is HesperCo and was approved by the Canadian authorities a few weeks ago. At the beginning of November, the capsules will be on the shelves of all major retailers in Canada.

President and Chief Executive Officer of Valeo Pharma, Steve Saviuk, commented as follows: "We have high expectations for HesperCo, which will be launched nationally in the coming weeks, as the immune support it provides is needed in the current health care environment. We continue interacting with Health Canada in the review of Redesca (low-molecular-weight Heparin biosimilar) and are preparing for an early 2021 launch, pending its expected approval."

Broad range

In addition to HesperCo, the North Americans market innovative prescription products with a focus on neurodegenerative diseases, oncology products, and speciality products for hospitals in Canada. At the end of September, a total of CAD 6.9 million has been raised from investors. The money raised is to strengthen sales and fill the pipeline of future-oriented products.


Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

02. November 2020 | 09:07 CET | by Stefan Feulner

Ballard Power, Saturn Oil & Gas, Amazon - The profiteers of the crisis!

  • Covid-19

The profiteers of the first wave of the Corona pandemic are seen from the most recently published quarterly figures. The well-known FAANG stocks Facebook, Amazon, Apple, Netflix and Alphabet (Google) were able to improve their balance sheets significantly. Besides some winners, the number of losers is much larger. These now either have to fight for survival or are swallowed cheaply by financially more robust competitors. The takeover wave should pick up speed in 2021, across all industries!


23. September 2020 | 09:05 CET | by Mario Hose

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.


18. September 2020 | 06:00 CET | by Mario Hose

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

  • Covid-19

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.